Eureka Therapeutics, Inc.

Overview

• IndustryBiological Products, (No Diagnostic Substances)²
• HeadquartersEmeryville, United States²
• Legal formCorporation²
• LEI549300XW368SBE7KX822²
• StatusActive²
• LEI statusLapsed (not renewed)²
• Registered addressC/O The Corporation Trust Company, 19801 Wilmington, United States²
• Registered withDivision of Corporations, Department of State, 6700219²

See how the biggest companies compare on our leaderboards

Corporate structure

Eureka Therapeutics, Inc. sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); stakes of 5% or more it reported on Schedules 13D and 13G (1 companies). Each entity in the chart links to its source.

Leadership

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive Officer, DirectorCheng Liu named May 17, 2023³
• Executive OfficerVictor S. Shum named May 17, 2023³
• Executive OfficerVivien S. Chan named May 17, 2023³
• DirectorChih-Kai "C.K. Cheng named May 17, 2023³
• DirectorJacqueline Northcut named May 17, 2023³
• DirectorMarvin Samson named May 17, 2023³
• DirectorMichael Cannon named May 17, 2023³
• DirectorReed Jobs named May 17, 2023³
• DirectorWai-Yan "Sandy" Chau named May 17, 2023³
• DirectorWilliam S. Solari III named May 17, 2023³

Calendar

Drug trials and FDA: coming up

1. Jul 31, 2027Phase 1/2 trial readout expected Phase 1/2 trial of EB103 in B-Cell Non-Hodgkin's Lymphoma (NHL), run by Estrella Immunopharma, Inc.: primary completion expected Jul 31, 2027 (ClinicalTrials.gov NCT06343311).⁴

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

1 filings to the SEC since October 2021: 1 private raises. The latest 1:

1. May 17, 2023D EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Stakes it holds

Eureka Therapeutics, Inc. has told the SEC it owns more than 5% of 1 company, latest first (Schedules 13D and 13G).

• Estrella Immunopharma, Inc.SC 13D Oct 30, 2023⁵

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. May 17, 2023Filed a private offering of debt³ Form D: $20 million offered in all Form D